MBOT

Microbot Medical Inc. (MBOT) - 10-K Filing Summary

Business Context and Reporting Period

Company: Microbot Medical Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Microbot is a medical device company developing the LIBERTY® Endovascular Robotic Surgical System, a fully disposable, compact robot for minimally invasive endovascular procedures. The company operates primarily in the U.S. and Israel. As of the reporting date, the company has not recognized any product revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Liquidity Surge: Total cash and marketable securities increased from $5.47 million in 2024 to $78.59 million in 2025. This was driven by significant financing activities, including registered direct offerings, private placements, and the exercise of preferred investment options, raising approximately $86.2 million in net cash from financing activities.
• Expense Growth: Sales, General, and Administrative (SG&A) expenses increased by $3.47 million (69%) to $8.46 million, primarily due to new hires for commercialization, increased professional fees, and marketing activities. R&D expenses decreased slightly by $0.35 million due to higher government grants recognized as contra-expenses.
• Inventory Build-up: The company recorded $0.58 million in inventory for the first time in 2025, following FDA clearance in September 2025, whereas no inventory was recognized in 2024.
• Financing Income: Financing income increased to $1.29 million from $0.18 million, driven by market gains on marketable securities.

Guidance, Outlook, and Risks

• Commercialization Timeline: The company received FDA 510(k) clearance for the LIBERTY® system in September 2025. A limited market release occurred in November 2025. Full market release is planned for April 2026 at the Society of Interventional Radiology conference.
• Regulatory Milestones: The company anticipates CE Mark approval for Europe in the second half of 2026. It has received ISO 13485:2016 certification.
• Profitability Outlook: Management expects to continue incurring significant operating losses for the foreseeable future as it ramps up manufacturing and commercialization. There is no assurance the company will ever achieve profitability.
• Capital Needs: While management believes current funds are sufficient for operations for over one year, the company expects to need additional funding to sustain its business model and may raise capital through equity or debt offerings.
• Key Risks:
  • Geopolitical Conflict: Operations in Israel are subject to risks from ongoing military actions (including the "Epic-Fury" operation in February 2026), which could disrupt supply chains, mobilize employees, or impact international trade.
  • Single Product Dependence: The business relies entirely on the success of the LIBERTY® system.
  • Reimbursement: Success depends on obtaining adequate third-party reimbursement, which is uncertain.
  • Manufacturing: The company relies on third-party manufacturers and is ramping up production capacity.

Investor Verification Checklist

• Revenue Recognition: Verify the timing and magnitude of the first commercial sales following the April 2026 full market release.
• Capital Runway: Confirm the burn rate post-commercialization launch and the sufficiency of the $78.6 million liquidity position.
• Regulatory Status: Monitor progress toward CE Mark approval in Europe and any FDA post-market surveillance requirements.
• Geopolitical Impact: Assess the actual impact of the Middle East conflict on Israeli manufacturing, supply chain logistics, and employee availability.
• Reimbursement Strategy: Evaluate the company's progress in securing CPT codes or reimbursement agreements with major payors.
• Dilution Risk: Review the terms of outstanding warrants and preferred investment options (approx. 16.3 million warrants outstanding as of Dec 31, 2025) and potential future equity raises.